P. Hamer

发表

A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel

G. Mosialos, P. Hamer, A. Capobianco, 1991, Molecular and cellular biology.

Generation of monoclonal antibodies specific for ras p21 Glu-12 oncoproteins: detection in carcinogen-induced mammary carcinomas.

M. Barbacid, S. Sukumar, I. Leav, 1991, Hybridoma.

Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.

H. Nielsen, N. Brünner, D. Jarosz, 1999, Clinical chemistry.

Production and characterization of monoclonal antibodies to Ha-ras and N-ras p21.

W. Carney, P. Hamer, J. Lavecchio, 1991, Hybridoma.

A monoclonal antibody reactive with an activated ras protein expressing valine at position 12

W. Carney, G. Cooper, P. Hamer, 1986, Journal of cellular biochemistry.

Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer

W. Carney, P. Hamer, L. Demers, 2006, Cancer.

Mechanism of stimulation of prostaglandin synthesis by a factor from rheumatoid synovial tissue.

M. Stephenson, P. Hamer, D. Robinson, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancer

W. Carney, P. Hamer, L. Demers, 2007, Cancer.

Detection and quantitation of the human neu oncoprotein

S. Naber, D. Hayes, D. Kufe, 1991 .

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.

W. Carney, P. Hamer, L. Demers, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activated Val-12 ras p21 in cell culture fluids and mouse plasma.

W. Carney, P. Hamer, H. Wolfe, 1991, Oncogene.

Monoclonal antibody specific for an activated RAS protein.

A. Tischler, C. Der, W. Carney, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Production and characterization of anti-RAS p21 monoclonal antibodies.

W. Carney, P. Hamer, H. Wolfe, 1990, Hybridoma.

Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

W. Carney, P. Hamer, L. Demers, 2005, Cancer.

Elevated levels of pro-cathepsin-d in the plasma of breast-cancer patients.

D. Jarosz, P. Hamer, D. Tenney, 1995, International journal of oncology.

Elevated plasma tissue inhibitor of metalloproteinase‐1 levels predict decreased survival in castration‐resistant prostate cancer patients

P. Kantoff, W. Oh, M. Regan, 2011, Cancer.

Pretreatment serum uPA and survival in patients with advanced pancreatic cancer.

W. Carney, P. Hamer, L. Demers, 2004, Journal of Clinical Oncology.

Serum urokinase-type plasminogen activator (UPA) as a prognostic factor in metastatic breast cancer

W. Carney, P. Hamer, A. Lipton, 2001 .

Serum EGFR/HER-2 combination predicts poor survival in metastatic breast cancer

W. Carney, P. Hamer, L. Demers, 2005 .

Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.

W. Carney, P. Hamer, K. Trimpe, 1990, Oncogene.

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.

M. Dimopoulos, W. Carney, P. Hamer, 2010, Leukemia research.